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years. 2015 Medicare deductibles and co-insurance rates were used to estimate 
spend for LAAC, acute clinical events and office visits. Average drug costs were 
calculated from the four states with the largest number of Medicare beneficiar-
ies. Patient stay days were taken from HCUP and inpatient rehabilitation prospec-
tive payment system data. Clinical probabilities for LAAC and warfarin were taken 
from PROTECT AF 4-year data and for dabigatran from the RE-LY trial. Results: 
The deductible for the LAAC procedure was $1,260. This compares to an average 
annual acquisition cost of roughly $345 for warfarin and $1,048 for dabigatran. First 
year total costs were $1,734, $1,023 and $1,335, for LAAC, warfarin and dabigatran, 
respectively. By the end of year 2, LAAC was less expensive with total costs of $2,353 
compared to $2,702 (warfarin) and $2,865 (dabigatran). By year 5, LAAC was approxi-
mately half the cost of anticoagulants. ConClusions: Patient out-of-pocket costs 
for stroke prevention in AF are considerable and may represent a burden for many 
Medicare beneficiaries living on fixed incomes. LAAC with the Watchman Device 
provides lifetime stroke prophylaxis without increased bleeding risk at a lower 
cost to patients.
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objeCtives: Bleeding in liver surgery can be difficult to control due to extreme 
vascularity and tissue fragility, including compromised liver (e.g., cancer). Blood 
loss may be minimized with hemostats that have rapid effect and may impact cost 
of care. This study estimated budget impact of using EVARREST vs. SoC in hepatic 
surgery based on two randomized trials. Methods: An economic analysis was 
developed to quantify 30-day cost impact of EVARREST from a U.S. hospital per-
spective. Key resources, from two randomized trials (n=180), included initial treat-
ment, retreatment, operating time, transfusions, ventilator, and hospitalization. 
Transplant patients (n=6) where normal liver tissue was resected were excluded 
from analyses.  SOC was composed mainly of manual compression alone or with 
hemostats. The surgical analysis included resources clinically related to significant 
hemostasis benefits of EVARREST (i.e. retreatment, operating time, transfusion). A 
hospital analysis included all resources collected. Economic analyses were com-
pleted for the following subgroups: abnormal liver, metastatic cancer, anatomic/
non-anatomic liver (classifications using IHPBA definitions), cirrhotic/steatotic liver, 
and if patients were obese or coagulopathic. Published U.S. costs were applied to 
resource use. Analysis results were weighted based on trial size. Results: The 
surgical analysis predicted that the EVARREST cost was offset vs. SoC with a trial-
weighted cost impact of $719 per patient.  The hospital analysis predicted further 
resource reduction with EVARREST with trial-weighted cost-savings of $868 per 
patient.  Subgroup analyses demonstrated a range of results from cost impact to cost 
savings with EVARREST vs. SOC (i.e., $1,976 to -$5,430 per patient, hospital analysis). 
EVARREST use in coagulopathic patients was found to have the largest degree of 
cost savings with $1,859 and $5,176 per patient anticipated, surgical and hospital 
results respectively. ConClusions: In addition to meeting an important unmet 
need in controlling problematic bleeding in liver tissue, this analysis suggests that 
EVARREST can be a cost saving strategy.
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objeCtives: Anti-epidermal growth factor receptor (EGFR) therapies are ineffective 
in tumors with KRAS mutations in exon 2 codons 12 and 13. Thus, guidelines have 
recommended determination of KRAS mutation status in metastatic colorectal can-
cer (mCRC). Both the cobas® KRAS Mutation Test (cobas® test, currently available as 
Research Use Only in the US) and the therascreen KRAS RGQ PCR Kit (therascreen 
test) detect KRAS mutations in exon 2; cobas® test detects twelve mutations and 
therascreen test detects seven mutations in exon 2. We estimated the potential 
clinical and budgetary impact of using the cobas® test versus therascreen test in 
the mCRC setting. Methods: A budget impact model comparing the clinical and 
economic outcomes of using the cobas® test versus therascreen test was devel-
oped from the US payer perspective. We assumed 42,000 annual cases of mCRC 
patients. Model inputs were obtained from literature, whereas testing and treat-
ment costs were calculated from CMS reimbursement rates. KRAS test sensitivity 
reflected the test’s ability to detect mutations in codons 12 and 13; specificity was 
assumed to be the same for both tests. The model calculated the average cost for 
mCRC patients over 5 years, using median time on treatment and median overall 
survival. Based on current practice patterns, the proportion of patients receiving 
KRAS testing before 1st-line, 2nd-line, and 3rd-line therapy were 42%, 32%, and 
26%, respectively. Results: Adopting the cobas® test resulted in a reduction of 289 
patient-months lost due to non-optimal care (i.e. by avoiding anti-EGFR therapies in 
mutant positive patients) and an improvement in median overall survival. Adopting 
the cobas® test generated a total of $2.3 million in cost savings and an average 
decrease of $7 per mCRC patient per month. ConClusions: Using the cobas® test 
with improved sensitivity was associated with a reduction of patient-month lost 
and a decrease of healthcare costs in mCRC patients.
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years, while low risk patients exceeded it in 15 years, respectively. Coexisting risk 
resulted in a sharp increase in the incidence of CRC exceeding the benchmark risk 
in less than 3 years. ConClusions: Intervals based on incidence of CRC diverge 
from adenoma only surveillance recommendations and suggest a longer interval 
of follow-up except for those with co-existing risk.
MEDical DEvicE/DiaGnostics - cost studies
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objeCtives: Depending on the penetration of screening recommendations, it is 
possible that the incidence of detected pulmonary nodules (PNs) could increase 
exponentially in coming years. Currently PN evaluation routinely requires costly 
procedures including imaging, biopsy and surgery. A molecular blood based test that 
measures plasma proteins using selected reaction monitoring mass spectroscopy 
allows for an objective and quantitative assessment of PN benignity. This budget 
impact analysis was performed to quantify the molecular test impact on a US com-
mercial health plan’s direct medical costs. Methods: The budget impact model 
was developed from a commercial health plan perspective, with direct medical costs 
estimated from the MarketScan® reimbursement benchmark data. Total PN diag-
nostic evaluation costs were estimated for a 2-year time horizon and were calculated 
for the current standard of care and care with the introduction of the molecular 
test. Diagnostic procedure resource utilization was obtained from a retrospective 
chart review analysis of a geographically representative sample of indeterminate 
PNs (8-20mm) managed by outpatient pulmonologists. Results: Currently, 52% 
of PNs are evaluated with an invasive procedure (biopsy/surgery) and 48% with 
surveillance alone, with significant cost differences observed between these two 
groups. The base case analysis using a health plan of one million members and a 
rate of 0.25% PNs within the health plan, estimated a 27% reduction in avoidable 
invasive procedures with the introduction of the molecular test. This amounted 
to a total potential cost savings of 20% from procedure and complication avoid-
ance. ConClusions: Adoption of this molecular test may help reduce the number 
of unnecessary invasive procedures being performed for individuals presenting with 
indeterminate pulmonary nodules. The reduced resource utilization can result in 
cost savings for the health plan.
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objeCtives: There is a strong correlation between cardiovascular disease and dia-
betes with management of blood pressure (BP), blood glucose (BG), and lipids being 
essential to preventing disease progression and complications. The FDA-cleared 
Proteus device captures and shares information about medication-taking, rest and 
activity patterns through a mobile device and app, a patch with a wearable sensor 
inside, and sensor-enabled pills. This offering facilitates patient engagement and 
behavioral change, informative provider decision-making, and improvement of out-
comes. An economic model was developed to estimate the impact of reducing BP, 
BG, and lipids via the Proteus offering. Methods: The value of 1-month use of the 
Proteus offering to reduce BP, BG, and lipids was evaluated in patients with comorbid 
hypertension, type 2 diabetes, and hypercholesterolemia from a US payer perspec-
tive for a 1-year time horizon. The clinical and utilization assumptions were derived 
from the literature, expert opinion, and a real-world Proteus study in patients with 
uncontrolled hypertension. Costs were derived from the Medicare Fee Schedule 
and AHRQ databases. Payers were also interviewed for current management of 
these conditions as input to the model. Results: The cost offsets of the Proteus 
service offering were estimated to be $90-185 per month of use, including current 
reimbursement for medications and medication adherence solutions. Medical cost 
savings consisting of reductions in outpatient and inpatient services, monitoring, 
disease management, and medication costs were estimated to be $850-980 per 
patient per year (PPPY), which was mainly driven by a 5-11% reduction in diabetes 
and CVD complications. Revenue opportunities via meeting quality measures pre-
sented an additional value equating to $80-95 PPPY, bringing the total value of the 
Proteus offering to $1020-1260 PPPY. ConClusions: The Proteus offering provides 
opportunities to mitigate the high costs of managing at-risk patients with multiple 
cardiometabolic comorbidities.
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objeCtives: Healthcare costs today are increasingly being shifted from payers to 
patients, yet few providers factor patient costs into treatment decisions. Recent 
advancements in stroke prevention in atrial fibrillation (AF) have resulted in new 
treatment options where previously there were few. While the clinical benefit and 
cost effectiveness of these treatments are supported by a growing body of evi-
dence, the cost impact to patients has not been explored. This analysis sought to 
quantify patient out-of-pocket costs for three stroke prevention strategies: war-
farin, dabigatran and left atrial appendage closure (LAAC) with the Watchman 
Device. Methods: A patient-level budget impact model was used to assess total 
out-of-pocket spend on treatment and treatment-related complications over five 
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objeCtives: Demonstrating economic value of new products is important for hos-
pitals adoption. The combination of two devices: ETHICON SECURESTRAP® Open 
Absorbable Strap Fixation Device and ETHICON PHYSIOMESH™ Open Flexible 
Composite Mesh Device, offers a standardized approach to open IPOM repair 
of ventral hernia. This analysis assesses the potential economic value of using 
these devices when compared with other meshes and a hand-sutured fixation 
approach. Methods: An economic model was developed to evaluate the budget 
impact to hospitals adopting ETHICON SECURESTRAP™ Open Fixation Device with 
ETHICON PHYSIOMESH™ Open in ventral hernia repair. A 1- to 3-year time horizon 
was included in the Excel-based model. An increasing utilization rate for ETHICON 
SECURESTRAP™ Open (20% - 60%), and ETHICON PHYSIOMESH™ Open (10% - 30%) 
was assumed over 3-year horizon. Costs of the mechanical fixation device, suture 
supplies, mesh, OR time, anesthesia time, and potentially avoided surgical site infec-
tions were considered. The differences in total costs were calculated. Results: 
Based on the model inputs, a 3-year total potential saving of $240,650 was estimated 
for 100 annual open ventral hernia surgeries using ETHICON SECURESTRAP™ Open 
Fixation Device versus suture of various meshes. Over three years, although the use 
of ETHICON SECURESTRAP™ Open Fixation Device added $54,600 in supplies costs, 
this was completely offset by potential savings in OR time costs ($167,520), potential 
reduction in avoided surgical site infection or seroma costs due to shorter operat-
ing room time ($126,903), and potential reduction in anesthesia costs ($17,189). 
Similarly, a savings of $40,108 was expected in the very first year. ConClusions: 
This analysis represents the first economic evaluation of ETHICON SECURESTRAP™ 
Open Fixation Device with ETHICON PHYSIOMESH™ Open in open ventral hernia 
surgery. Adoption of the two devices would likely result in savings for hospitals, 
driven by shorter procedure time and related expected clinical benefits.
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objeCtives: Peripheral artery disease affects 8-10 million U.S. adults and 50% 
involve femoropopliteal arteries. A novel treatment, the Lutonix®035 Drug Coated 
Balloon PTA catheter (DCB) is indicated for percutaneous transluminal angioplasty 
(PTA), after pre-dilatation, of de novo or restenotic lesions up to 150mm in length 
in native superficial femoral or popliteal arteries with reference vessel diameters 
of 4-6mm. These analyses estimated the potential cost impact of DCBs vs. current 
care. Methods: These economic modeled analyses compared total costs with vs. 
without DCBs over one year in a real-world scenario treatment mix for femoro-
popliteal PAD; these analyses were not based upon head-to-head clinical compari-
sons. For the inpatient hospital perspective, DCBs were compared with PTA, bare 
metal stents (BMS), drug-eluting stents (DES), covered stents (CS), and atherectomy. 
For the outpatient perspective, DCBs plus short spot stents were compared with 
BMS, DES, CS, and atherectomy. Equal distribution of treatment options in a world 
with vs. without DCBs was assumed. Consumable device-related costs (based upon 
published costs, where available) associated with initial procedures and repeat 
procedures (i.e., estimated target lesion revascularizations (TLRs)) were included. 
Average device utilization was informed by RCTs and TLR risk was derived from 
a network meta-analysis. Alternative analyses, including incremental reimburse-
ment for DCBs, or different utilization/comparator assumptions, were also evalu-
ated. Results: When including DCBs into the mix of treatments (1,000 patients) 
one-year cost-savings were estimated to be $74,735 and $104,688 for inpatient and 
outpatient hospital perspectives, respectively. Additionally, DCBs were predicted 
to be cost-saving in the majority of analyses vs. individual therapies (e.g., DCB 
vs. CS: -$2,202 to -$2,967 per patient). Alternative analyses assuming incremental 
reimbursement predicted that DCBs could provide even greater cost-savings under 
a Medicare payment scenario. ConClusions: These analyses suggest that DCBs 
may provide cost-savings from a hospital perspective when considering the full 
range of comparators.
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objeCtives: Sufficient tissue sample is not always available for EGFR mutation 
testing to direct treatment with tyrosine kinase inhibitors in NSCLC patients. We 
compared the impact of using the FDA-approved cobas® EGFR Mutation Test alone 
versus using blood-based cobas® EGFR Mutation Test as an alternative test for 
patients without adequate tissue sample in NSCLC patient treatment decision-
making in the US. Methods: A decision-tree model was developed to compare 
testing methodologies and resulting treatment pathways in a hypothetical NSCLC 
US population health plan with 5 million covered lives and a baseline EGFR muta-
tion prevalence of 16%. Inputs were based on published literature and Medicare 
fee schedule reimbursement. Outcomes of the model included patients with test 
failures, average patient survival time, and budget impact. The combination of tis-
sue and blood-based testing were examined in four different scenarios. Results: 
Blood-based EGFR mutation testing is a more accessible method for identifying 
EGFR mutation status for patients without a tissue sample. More patients received 
objeCtives: Mastectomy and lumpectomy procedures are often carried out using 
electrocautery; however, clinical evidence has demonstrated that the use of ultra-
sonic energy may reduce blood loss, seroma formation, wound infection, flap necro-
sis, hematoma, prolonged axillary drainage and length of stay. In the Canadian 
healthcare environment hospitals are faced with increasingly restrictive budgets, 
creating a critical need to demonstrate the cost-effectiveness of new technolo-
gies. This study was conducted to determine whether the reduction in complica-
tions associated with the use of ultrasonic energy in mastectomy and lumpectomy 
procedures offsets the increased device costs in a Canadian hospital. Methods: 
We examined the budget impact of replacing electrocautery devices with ultra-
sonic energy in a hospital that performs 100 lumpectomies and 100 mastectomies 
annually. The model incorporates the costs associated with surgery, length of stay 
(taking into account facility and staff costs) and postoperative complications. The 
cost data was obtained from the Ontario Case Costing Initiative and case costing 
from a large Canadian hospital. Patient outcomes data was obtained from pooling 
published, peer reviewed literature after completing a comprehensive literature 
review. A multivariate sensitivity analysis was completed to ensure scientific rig-
our. Results: The use of electrocautery in mastectomy and lumpectomy proce-
dures is associated with lower device costs when compared to the use of ultrasonic 
energy devices. However, mastectomies and lumpectomies completed with ultra-
sonic energy devices demonstrate reduced operating time, a reduction in length of 
stay and a reduction in post-operative complications which offsets the increased 
device costs. The model establishes that replacing electrocautery with ultrasonic 
devices in a Canadian hospital performing 100 mastectomies and 100 lumpectomies 
annually would allow for a potential cost avoidance of $171,966. ConClusions: In 
a Canadian hospital, the use of ultrasonic energy in mastectomy and lumpectomy 
procedures provides a cost savings when compared to the use of electrocautery.
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objeCtives: Canadian hospitals spend an estimated $111 million annually on elec-
tive AAA repair. Percutaneous endovascular abdominal aortic repair approach (PEVAR) 
is a new minimally invasive technique that avoids surgical cut down associated with 
standard endovascular AAA repair (EVAR). Innovations in access devices and low pro-
file stent grafts have enabled the PEVAR approach. According to recent studies, PEVAR 
may offer substantial efficiency benefits as well as a reduction in post-operative 
complications and patient pain. The objective of our study was to evaluate the budget 
impact to a hospital of changing the technique for AAA repair from the EVAR approach 
to the PEVAR approach. Methods: We examined the budget impact of replacing 
the EVAR approach with the PEVAR approach in a Canadian hospital that performs 
100 endovascular AAA repairs annually. The model incorporates the costs associated 
with surgery, length of stay and postoperative complications occurring within 30 
days. The cost data used in the model was obtained from peer reviewed literature, 
the Ontario Case Costing Initiative and case costing from a large Canadian hospital. 
Patient outcomes data was obtained from pooling published prospective studies after 
completing a comprehensive literature review. A multivariate sensitivity analysis was 
completed. Results: The use of PEVAR in AAA repair is associated with increased 
access device costs when compared to the EVAR approach. However, AAA repair com-
pleted with the PEVAR approach demonstrate reduced operating time, a reduction 
in length of stay and time in the recovery room and a reduction in post-operative 
complications which offset the increased device costs. The model establishes that 
switching to the PEVAR approach in a Canadian hospital performing 100 AAA repairs 
annually would result in a potential cost avoidance of $245,130. ConClusions: A 
change in AAA repair technique from EVAR to PEVAR can be a cost-effective solution 
for Canadian hospitals.
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objeCtives: Diabetes (DM) is prevalent among hospitalized patients making insulin 
administration a regular practice in acute care. Variability in the method of adminis-
tration leaves room for optimization. A budget impact model was created to evaluate 
the impact of passive SPN on healthcare worker safety and HRU in the acute care 
setting. Methods: Model inputs include fixed assumptions of insulin waste and 
cost, needle stick injury (NSI) rates from safety syringe (SS) and SPN, nursing time, 
and supply costs. Inputs were obtained from the literature and real-world pilot 
studies. The model compares 4 scenarios using insulin vial with SS versus using 
insulin pens with SPN: 1) SS+10mL vial patient supply, 2) SS+10mL vial floor stock, 
3) SS+3mL vial patient supply, 4) SS+3mL vial floor stock. Results: Using insulin 
pens with SPN reduced NSIs, decreased nursing time, and increased injection sup-
ply cost. Insulin consumption varies based on the scenario and affects economic 
outcomes. When applying real-world data from a 52-bed pilot study to each scenario, 
annual cost savings (+) or expenditures (-) from switching to SPN are as follows: 
1) +$27,622, 2) -$5,951, 3) +$18,730, 4) -$14,485. ConClusions: The cost of NSI 
contributes significantly to total HRU in the acute care setting in the US. Benefits 
of switching to SPN include reducing NSIs and decreasing nursing time needed to 
prepare an insulin injection. For individual patient supply scenarios (scenarios 1 
and 3), switching to SPN can reduce both NSIs and total cost to the institution. It 
is important to note that although the real-world pilot study results above are not 
generalizable, the model is adaptable to any institution based on number of beds 
and yearly insulin consumption. NSI rates may be underestimated, and in these 
cases, adoption of SPN may have a positive budget impact while improving health 
care worker safety.
